ad image

Samsung Bioepis Co., Ltd.

1 / 1
Samsung Biologics
Investment

Samsung Invests in Generate: Biomedicines to Advance AI-Driven Protein Therapeutics Discovery

Samsung Biologics

PR-12-24-NI-141Dec 18, 2024
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Pharma's Almanac

PAO-06-022--RT-01Jun 24, 2022
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Pharma's Almanac

O-06-022--RT-01Jun 24, 2022
Samsung Biologics
M&A

Samsung Biologics Reaches Agreement With Biogen to Acquire Full Ownership of Samsung Bioepis

Samsung Biologics

PR-M01-22-21Jan 28, 2022
Samsung Bioepis
Biosimilar

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

Samsung Bioepis

PA2329Jul 26, 2019
Samsung Bioepis
Phase I

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

Samsung Bioepis

PR-M09-18-NI-007Sep 05, 2018
Samsung to Develop Novel Drugs
Partnership

Samsung to Develop Novel Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M09-17-NI-002Sep 01, 2017
Collaboration Seeks Novel Pancreatitis Therapies
Partnership

Collaboration Seeks Novel Pancreatitis Therapies

Nice Insight

PAO-M08-17-NI-037Aug 29, 2017
1 / 1